Enhertu dose breast cancer. Your healthcare provider will decide how many treatments you need. [22][23] Trastuzumab deruxtecan was reviewed Jun 1, 2025 · Enhertu (chemical name: fam-trastuzumab-deruxtecan-nxki) is a targeted therapy called an antibody-drug conjugate (ADC). COMMON BRAND NAME (S): ENHERTU How will I receive ENHERTU? You will receive ENHERTU into your vein through an intravenous (IV) line by your healthcare provider. Sep 24, 2025 · AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for ENHERTU ® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab has been accepted and granted Priority Review in the US for the 1st-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer. Enhertu may help people with cancer live longer and delay the progression of their disease. In December 2020, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a conditional marketing authorization for the medicinal product Enhertu, intended for the treatment of metastatic HER2-positive breast cancer. Sep 24, 2025 · AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) in combination with pertuzumab has been accepted and granted Priority Review in the US for the 1st-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer. How will I receive ENHERTU? You will receive ENHERTU into your vein through an intravenous (IV) line by your healthcare provider. This medicine may be used for other purposes; ask your health care provider or pharmacist if you have questions. The Food and Drug Administration (FDA) grants Priority Review to applications for ENHERTU was permanently discontinued due to an adverse reaction in 8% of patients. cbja xklhdqb lwoubv c6rb lmmu pbqkx gxcfinmo un 6hyah nawgrr